Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 9,001–9,100 of 15,747
Estimates of Presumed Population Immunity to SARS-CoV-2 by State in the United States, August 2021
Stoner, M. C. D., Angulo, F. J., Rhea, S. K., Brown, L. M., Atwell, J. E., Nguyen, J. L., McLaughlin, J. M., Swerdlow, D. L., & MacDonald, P. D. M. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab647 · Cited by 6
“9 (72% in US subsample[18,19]), Moderna (94%[20]), and Pfizer-BioNTech (95%[21]).”
BackgroundMcDonald, S., Basit, M. A., Toomay, S. M., McLarty, C., Hernandez, S., Rubio, C., Brown, B. J. L., Rauschuber, M., Lai, K., Saleh, S. N., et al. (2021) · Applied Clinical Informatics · doi:10.1055/s-0041-1739517 · Cited by 6
González‐López, T. J., Bárez, A., Bernardo, Á., Bernat, S., Canaro, M., Entrena‐Ureña, L., Fernández‐Fuertes, F., de Castro, J. M. G., Jiménez‐Bárcenas, R., Pascual, C., et al. (2022) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00745-2 · Cited by 6
Weng, X., Chen, Q., Sathapathi, T. K., Yin, X., & Wang, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-37980-7 · Cited by 6
“For simplicity, our model did not specify the types of vaccine and assumed an overall protection effect of 90% reduction in the transmission probability, based on early evidence on the protective effect of vaccines reflected in the reduction of hospitalization 76,77 .”
MethodPaggi, R., Barbiero, A., Manciulli, T., Miftode, A., Tilli, M., Lagi, F., Mencarini, J., Borchi, B., Pozzi, M., Bartalesi, F., et al. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03231-w · Cited by 6
Tayhan, A., Tayhan, E. B., & Büyük, D. Ş. (2025) · Nursing and Health Sciences · doi:10.1111/nhs.70039 · Cited by 7
Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19
Chang, A., & Yu, J. (2022) · Viruses · doi:10.3390/v14020380 · Cited by 7
“Second, BNT162b2 and mRNA-1273 COVID-19 vaccines were shown to generate a partially protective immune response against symptomatic SARS-CoV-2 infection just days after immunization [79,80].”
BackgroundRatajczak, P., Banach, Z., Kopciuch, D., Paczkowska, A., Zaprutko, T., Krawczyk, J., Maciuszek-Bartkowska, B., & Kus, K. (2023) · Healthcare · doi:10.3390/healthcare11111532 · Cited by 6
“2020 [14] Tozinameran New England Journal of Medicine 6825 Sahly et al.”
BackgroundInfluentialRaikhel, A. V., Blau, K., Alberty, K., Cornia, P. B., Rodriguez, R. A., Steinberg, K. P., & Wu, C. (2022) · American Journal of Medical Quality · doi:10.1097/jmq.0000000000000094 · Cited by 7
Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees
Jäger, M., Sonnleitner, S. T., Dichtl, S., Lafon, E., Diem, G., Walder, G., Lass‐Flörl, C., Wilflingseder, D., & Posch, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.868361 · Cited by 8
The South African Response to COVID-19: The Early Years
Fourie, P. P., & Lamb, G. (2023) · Routledge eBooks · doi:10.4324/9781003294931 · Cited by 13
Horndler, L., Delgado, P., Romero-Pinedo, S., Quesada, M., Balabanov, I., Laguna‐Goya, R., Almendro-Vázquez, P., Llamas, M. Á., Fresno, M., Paz‐Artal, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1157263 · Cited by 9
“The advent of Spike (S) protein-based mRNA COVID-19 vaccines have significantly improved the COVID-19 pandemic, with both Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1,273) reporting 95% vaccine efficacy (1, 3).”
BackgroundHealthcare resource use and costs among patients with COVID-19 in the United States
Liu, G., Done, N., Song, Y., Goswami, H., Wang, T., Li, H., Mattera, M., Signorovitch, J., & Hair, G. M. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12878-4 · Cited by 6
Mujukian, A., Kumar, R. N., Li, D., et al. (2023) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad114 · Cited by 6
Jin, G., Wang, R., Jin, Y., Song, Y., & Wang, T. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.1514 · Cited by 8
Ranjbar, S., Fatahi, Y., & Atyabi, F. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102899 · Cited by 6
“The BNT162b2, developed by the BioNTech/Pfizer/Fosun Pharma group, is also an mRNA-based LNP vaccine, which showed an efficacy of 95% among more than 43k participants enrolled in its phase 3 clinical trial [108].”
BackgroundLai, K. Z. H., Greenstein, S., Govindasamy, R., Paranilam, J., Brown, J. A., & Kimball-Carroll, S. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01052-8 · Cited by 6
“…mRNA‑1273 (Spikevax®, Moderna, Inc., Cam‑ bridge, MA, USA) [1] and BNT162b2 (Comir‑ naty®, Pfizer/BioNTech, New York, NY, USA/ Mainz, Germany) [2], both utilizing the novel messenger ribonucleic acid (mRNA) technology, as well as Nuvaxovid (Novavax), which employs a tradition protein subunits…”
MethodEosinophilic Granulomatosis With Polyangiitis Following COVID-19 Vaccination: A Case Report
Hwang, Y.-K., Kwak, H.-H., Yun, J.-E., Kim, S., & Chang, Y. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e382 · Cited by 7
Hodl, I., Sallegger, C., Forstner, P., Sareban, N., Moritz, M., Dreo, B., Schulz, E., Lackner, A., Kleinhappl, B., Hatzl, S., et al. (2023) · Microbes and Infection · doi:10.1016/j.micinf.2023.105103 · Cited by 7
Fathi, H. M., El-Gazzar, I. I., Elazeem, M. I. A., et al. (2022) · Rheumatology International · doi:10.1007/s00296-022-05130-3 · Cited by 6
Plausibility of Claimed Covid-19 Vaccine Efficacies by Age: A Simulation Study
Sheldrick, K. A., Meyerowitz‐Katz, G., & Tucker‐Kellogg, G. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001528 · Cited by 8
The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities
Shani, M., Hermesh, I., Feldhamer, I., Reges, O., Lavie, G., Arbel, R., & Sagy, Y. W. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.097 · Cited by 6
Updates on Coronavirus Disease 19 Vaccine and Its Clinical Application
Ahn, S. H., & Lee, S. H. (2021) · Korean Journal of Family Practice · doi:10.21215/kjfp.2021.11.4.236 · Cited by 6
Stone, S., Elsharkawy, A., Burleson, J. D., Hauser, M. J., Domi, A., Kumari, P., Nabi, Z., Natekar, J. P., Porto, M., Backstedt, B. T., et al. (2025) · Vaccines · doi:10.3390/vaccines13040411 · Cited by 8
“Rapid development, manufacture, and roll-out of first-generation vaccines afforded protection to vulnerable groups against the original strain of SARS-CoV-2 and early variants [2–5].”
Polyarteritis nodosa diagnosed in a young male after COVID-19 vaccine: A case report
Makiyama, A., Abe, Y., Furusawa, H., Kogami, M., Ando, T., Tada, K., Onimaru, M., Ishizu, A., Yamaji, K., & Tamura, N. (2023) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxad037 · Cited by 6
Gschwend, M. H., Marchese, A. M., Poelaert, D., Warren, B., Rousculp, M. D., & Caldera, F. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126777 · Cited by 7
Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models
Zirkenbach, V. A., Ignatz, R. M., Öttl, R., Cehreli, Z., Stroikova, V., Kaya, M., Lehmann, L., Preusch, M. R., Frey, N., & Kaya, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055011 · Cited by 7
Choi, W., & Shim, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132813 · Cited by 6
“A 95% disease risk reduction was considered in the sensitivity analysis, consistent with the effectiveness of Novavax [43], Pfizer-BioNTech [8], and Moderna [9] vaccines.”
ResultRecursive state and parameter estimation of COVID-19 circulating variants dynamics
Silva, D. M., & Secchi, A. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-18208-6 · Cited by 7
Biliotti, E., Caioli, A., Sorace, C., Lionetti, R., Milozzi, E., Taibi, C., Comandini, U. V., Maggi, F., Puro, V., & D’Offizi, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051320 · Cited by 7
“6% of participants with no better-defined liver disease received the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) mRNA vaccines in the registrative trials, respectively [7,8].”
BackgroundPlank, M. J., Binny, R. N., Hendy, S. C., Lustig, A. G., & Ridings, K. (2021) · Royal Society Open Science · doi:10.1098/rsos.210686 · Cited by 6
“The Pfizer/BioNTech mRNA vaccine being rolled out in New Zealand has been shown to have high effectiveness (greater than 90%) against symptoms [16,17] so the assumption, although conservative, is not unreasonable.”
BackgroundNasrullah, A., Gangu, K., Cannon, H. R., Khan, U., Shumway, N. B., Bobba, A., Sagheer, S., Chourasia, P. K., Shuja, H., Avula, S. R., et al. (2023) · Viruses · doi:10.3390/v15030600 · Cited by 7
“Additionally, mortality associated with AHF-COVID+ could have been mitigated with steroid use and vaccine administration, which were available after June and December 2020, respectively [31,32].”
BackgroundNano‐ and Microscale Drug Delivery Approaches for Therapeutic Immunomodulation
Paris, J. L., & Baeza, A. (2021) · ChemNanoMat · doi:10.1002/cnma.202100062 · Cited by 7
mRNA vaccines for prostate cancer: A novel promising immunotherapy
Tang, Y., Yi, X., & Ai, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189333 · Cited by 6
Myocarditis and pericarditis during COVID-19 pandemic: a study of the Italian Society of Cardiology
Birtolo, L. I., Pietro, G. D., D’Ascenzo, F., Cuccuru, G., Fabris, E., Merlo, M., Andreis, A., Matteo, C., Improta, R., Campo, G., et al. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001693 · Cited by 7
Campbell, J., Sutherland, J., Bucknall, D., O’Hara, L., Heywood, A. E., Hobbs, M., Ballantyne, A., & Gray, L. (2021) · Vaccines · doi:10.3390/vaccines9121466 · Cited by 8
“Global confidence in COVID-19 vaccination has been buoyed by large randomised controlled trials demonstrating high vaccine efficacy and excellent safety profiles [2,3].”
BackgroundWang, S.-C., & Chen, Y. (2022) · Vaccines · doi:10.3390/vaccines10122173 · Cited by 6
There Is No Evidence That Inactivated COVID-19 Vaccines Increase Risks of Uveitis Flare
Song, H., Zhao, C., & Zhang, M. (2022) · Vaccines · doi:10.3390/vaccines10101680 · Cited by 6
SARS-CoV-2 Vaccine-Induced Immune Responses Among Hematopoietic Stem Cell Transplant Recipients
Kokogho, A., Crowell, T. A., Aleissa, M. M., Lupan, A., Davey, S., Chang, J. B. P., Baden, L. R., Walsh, S. R., & Sherman, A. C. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad349 · Cited by 7
“Medications such as methotrexate, sirolimus, high-dose steroids, and mycophenolate mofetil commonly used in the management of GVHD among HSCT recipients have been implicated in poor SARS-CoV-2 vaccine immunogenicity among solid organ transplant recipients [2, 5, 6, 8, 17].”
Pawar, S., Pingale, P., Garkal, A., Osmani, R. A. M., Gajbhiye, K. R., Kulkarni, M., Pardeshi, K., Mehta, T. A., & Rajput, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131139 · Cited by 6
Liu, J., Wang, L., Kurtesi, A., Budylowski, P., Potts, K. G., Menon, H., Tan, Y., Samaan, P., Liu, X., Wang, Y., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01062-8 · Cited by 8
Risk-benefit analysis of emergency vaccine use
Lewis, G., & Bonsall, M. B. (2022) · Scientific Reports · doi:10.1038/s41598-022-11374-7 · Cited by 5
Buzas, D., Bunzel, H. A., Staufer, O., Milodowski, E., Edmunds, G. L., Bufton, J. C., Vidaña, B., Yadav, S. K. N., Gupta, K., Fletcher, C., et al. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad024 · Cited by 6
Refining the N-Termini of the SARS-CoV-2 Spike Protein and Its Discrete Receptor-Binding Domain
D’Ippolito, R. A., Drew, M. R., Mehalko, J. L., Snead, K., Wall, V. E., Putman, Z., Esposito, D., & DeHart, C. J. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00349 · Cited by 6
Milazzo, L., Pezzati, L., Oreni, L. M., Kullmann, C., Lai, A., Gabrieli, A., Bestetti, G., Beschi, C., Conti, F., Ottomano, C., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2002639 · Cited by 7
Cationic lipid nanoparticles for nucleic acid delivery: microfluidics versus thin film hydration
Park, H., Lee, J., Kang, J.-W., Min, J.-Y., Lee, J., Hong, J., & Shim, G. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00737-7 · Cited by 8
Hernández-Luis, P., Aguilar, R., Pelegrin-Pérez, J., Ruiz‐Olalla, G., García‐Basteiro, A. L., Tortajada, M., Moncunill, G., Dobaño, C., Angulo, A., & Engel, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816389 · Cited by 8
“Venous or finger prick blood was collected at different visits after recruitment and immunization with one or two doses of the mRNA-1273 (Spykevax) (16) or two doses of the BNT162b2 (Comirnaty) (17), products fromModerna Biotech and Pfizer-BioNTech, respectively.”
MethodCraig, L., Haloub, R., Reid, H., Masson, D., Mccalmont, H., Fodey, K., Conway, B. R., Lattyak, W. J., Lattyak, E. A., Bain, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9101160 · Cited by 5
“Vaccines have enabled the public to hope for a potential return to a more normal life despite the COVID-19 pandemic [14,15].”
BackgroundLi, Y., Wei, Z., Ma, X., Xu, J., Zhao, X., Cao, Q., & Di, G. (2021) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x16666211206145839 · Cited by 6
Next-Generation Allergen-Specific Immunotherapy for Food Allergy
Lee, J. Z. X., Sit, J. K. C., Leung, N. Y. H., Chu, K. H., Leung, P. S. C., Leung, T. F., & Wai, C. Y. Y. (2025) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-025-09104-8 · Cited by 10
“A large-scale phase 2/3 clinical trial of BNT162b2, a mRNA vaccine encoding the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has shown that it is efficacious in preventing COVID-19 in 95% of participants over 16 years of age [40].”
Díaz-Dinamarca, D. A., Díaz, P., Barra, G. N., Puentes, R., Arata, L., Grossolli, J., Riveros-Rodriguez, B., Ardiles, L., Santelises, J., Vásquez-Sáez, V., et al. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1229045 · Cited by 7
“4% in men who are 16–55 years old (4).”
BackgroundMethodWarkentin, L., Werner, F., Zeschick, N., Kühlein, T., Steininger, P. A., Überla, K., Kaiser, I., Sebastião, M., & Hueber, S. (2023) · BMC Medicine · doi:10.1186/s12916-023-02924-5 · Cited by 10
Public attitudes on social media toward vaccination before and during the COVID-19 pandemic
Shah, U., Biswas, M. R., Ali, R., Ali, H., & Shah, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2101835 · Cited by 7
Singh, K., Rocco, J. M., & Nussenblatt, V. R. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.08.002 · Cited by 6
Respiratory Virus Infections during the COVID-19 Pandemic Revealed by Multiplex PCR Testing in Japan
Yamashita, S., Ikegame, S., Nakatomi, K., Sakurai, Y., Shuto, H., Sato, N., Mizoguchi, Y., Uehara, M., Nakashima, N., Okamoto, I., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04162-22 · Cited by 6
“Despite the development of efficacious vaccines that elicit the production of protective antibodies (4), SARS-CoV-2 has acquired several mutations that allow it to evade immunity that has been conferred by earlier strains (5).”
BackgroundSon, C.-S., Jin, S. H., & Kang, W. (2022) · Vaccines · doi:10.3390/vaccines10020284 · Cited by 6
“after vaccination and resolving in most recipients by day 2 without sequelae [6,7].”
BackgroundResultCOVID-19 vaccines: a geographic, social and policy view of vaccination efforts in Ontario, Canada
Bogoch, I. I., & Halani, S. (2022) · Cambridge Journal of Regions Economy and Society · doi:10.1093/cjres/rsac043 · Cited by 9
Phenothiazines as dual inhibitors of SARS-CoV-2 main protease and COVID-19 inflammation
Forrestall, K. L., Burley, D. E., Cash, M. K., Pottie, I. R., & Darvesh, S. (2021) · Canadian Journal of Chemistry · doi:10.1139/cjc-2021-0139 · Cited by 7
Krylova, O., Kazmi, O., Wang, H., Lim, K., Logar‐Henderson, C., & Gapanenko, K. (2022) · International Journal for Population Data Science · doi:10.23889/ijpds.v5i4.1710 · Cited by 8
“Many local [5, 62–67] and national [7, 9, 68, 69] Canadian models and tools [11, 12, 70, 71] were developed to assist jurisdictional authorities and hospital planners with pandemic preparedness.”
BackgroundAchiron, A., & Tuuminen, R. (2022) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2022.101380 · Cited by 7
Modeling the first wave of Covid-19 pandemic in the Republic of Cyprus
Agapiou, S., Anastasiou, A., Baxevani, A., Nicolaides, C., Hadjigeorgiou, G. M., Christofides, T. C., Constantinou, E., Nikolopoulos, G. K., & Fokianos, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-86606-3 · Cited by 7
Abd-Elsayed, A. A., & D'Souza, R. S. (2022) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005858 · Cited by 6
Tomowiak, C., Leblond, V., Laribi, K., Baron, M., Puppinck, C., Gérard, P., Courret, E., Gorochov, G., Sterlin, D., Tournilhac, O., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18055 · Cited by 7
Stumpf, J., Schwöbel, J., Karger, C., Schirutschke, H., Mauer, R., Klimová, A., Tonn, T., & Hugo, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.910987 · Cited by 7
“Seroconversion rates for the general population after two doses of mRNA vaccination (3, 4) and the usefulness of a third vaccine booster dose, particularly for protection against new viral variants (5) have been reported.”
BackgroundAlpert, E. A., Herbst, R., Abramovich, I., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00058-1 · Cited by 6
Vaccine trials during a pandemic: potential approaches to ethical dilemmas
AlQahtani, M., Mallah, S. I., Stevenson, N. J., & Doherty, S. (2021) · Trials · doi:10.1186/s13063-021-05597-8 · Cited by 6
“Eight vaccines—including most notably Pfizer-BioNTech, Moderna, Oxford-AstraZeneca and Sinopharm—have received full approval for use by various countries, while eight others have received limited or emergency use authorization.”
MethodOptimizing SARS-CoV-2 vaccination strategies in France: Results from a stochastic agent-based modelPreprint
Hoertel, N., Blachier, M., Limosin, F., Rico, M. S., Blanco, C., Olfson, M., Luchini, S., Schwarzinger, M., & Leleu, H. (2021) · Research Square · doi:10.1101/2021.01.17.21249970 · Cited by 9
Ishiguro, C., Mimura, W., Uemura, Y., Maeda, M., Murata, F., & Fukuda, H. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad274 · Cited by 6
“This safety concern was not identified at the time of approval [2, 3]; however, many spontaneous case reports of HZ after COVID-19 vaccination have been published worldwide [4].”
SARS-CoV-2 infection outcomes associated with the Delta variant: A prospective cohort study
Gallant, M., Rioux‐Perreault, C., Lemaire‐Paquette, S., & Piché, A. (2022) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2022-0022 · Cited by 7
Sakai, A., Morishita, T., Suzumura, K., Hanatate, F., Yoshikawa, T., Sasaki, N., Lee, S., Fujita, K., Hara, T., Araki, H., et al. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2022.10.023 · Cited by 7
“There is a paucity of data in SOTs who use potent immunosuppressants because they have been specifically excluded from SARS-CoV-2 vaccine trials [1,2].”
BackgroundAdaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE studyPreprint
Fendler, A., Au, L., Boos, L. A., Byrne, F., Shepherd, S. T. C., Shum, B., Gerard, C. L., Ward, B., Xie, W., Cerrone, M., et al. (2020) · medRxiv · doi:10.1101/2020.12.21.20248608 · Cited by 6
Li, Q., Peng, J. C., Mohan, D., Lake, B., Euler, A. R., Weir, B. W., Kan, L., Yang, P., & Labrique, A. B. (2023) · JMIR Public Health and Surveillance · doi:10.2196/39166 · Cited by 5
Luo, J., Klett, J., Gabert, J., Lipp, T., Karbach, J., Jäger, E., Borte, S., Hoffmann, R., & Milkovska‐Stamenova, S. (2022) · Microorganisms · doi:10.3390/microorganisms10091812 · Cited by 9
The Delta Variant Had Negligible Impact on COVID-19 Vaccine Effectiveness in the USAPreprint
Blaiszik, B. J., Graziani, C., Olds, J. L., & Foster, I. T. (2021) · medRxiv · doi:10.1101/2021.09.18.21263783 · Cited by 7
“In the United States, three vaccines were subsequently approved for emergency use by the FDA based on the results of phase‘3 clinical trials: two employing mRNA technology (Moderna [9, 10] and Pfizer/BioNTech [11, 12]) and one employing a modified adenovirus (Janssen”
MethodCohen, D., Krauthammer, S. H., Cohen, Y. C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-395288/v1 · Cited by 6
Wratil, P. R., Kotter, K., Bischof, M. L., Hollerbach, S., Apak, E., Kalteis, A.-L., Pflantz, T., Kaderali, L., Adorjan, K., & Keppler, O. T. (2022) · Infection · doi:10.1007/s15010-022-01947-z · Cited by 8
Genome editing and cancer therapy: handling the hypoxia-responsive pathway as a promising strategy
Stampone, E., Bencivenga, D., Capellupo, M. C., Roberti, D., Tartaglione, I., Perrotta, S., Ragione, F. D., & Borriello, A. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04852-2 · Cited by 9
Chappell, K. J., Mordant, F. L., Amarilla, A. A., Modhiran, N., Liang, B., Li, Z., Wijesundara, D. K., Lackenby, J. A., Griffin, P., Bennet, J. K., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104842 · Cited by 7
Hartley, G. E., Fryer, H. A., Gill, P. A., Boo, I., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., Edwards, E. S. J., & van Zelm, M. C. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557929 · Cited by 6
“442 Primary BNT162b2 vaccination has a shorter window between dose 1 and dose 2 (3 443 weeks) (2) compared to ChAdOx1 (12 weeks) (5, 9).”
BackgroundMethodInfluentialImmune Thrombocytopenia Exacerbation After COVID-19 Vaccination in a Young Woman
Fujita, M., Ureshino, H., Sugihara, A., Nishioka, A., & Kimura, S. H. (2021) · Cureus · doi:10.7759/cureus.17942 · Cited by 6
“Safe and effective COVID-19 vaccines are urgently needed, developed to fight the pandemic [2-4], and then they are approved by the Food and Drug Administration (FDA).”
BackgroundPratesi, F., Errante, F., Pacini, L., Peña-Moreno, I. C., Quiceno, S., Carotenuto, A., Balam, S., Konate, D. S., Diakité, M., Arévalo‐Herrera, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879946 · Cited by 5
“Specifically, these features of the S protein led vaccine companies to choose it for vaccine development (13, 14).”
BackgroundLi, Q., Norman, S., Guthrie, P., et al. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab184 · Cited by 6
“One of the first vaccines granted emergency use authorization (EUA) by the US Food and Drug Administration (FDA) is made by Pfizer and BioNTech and was shown to provide 95% protection against COVID19 in people 16 years old or older in an ongoing multinational, placebocontrolled, observer-blinded trial.(3)”
BackgroundTwo Case Reports of Subacute Thyroiditis after Receiving Vaccine for COVID-19
Adelmeyer, J., Goebel, J. N., Kauka, A., & Kann, P. H. (2022) · Case Reports in Endocrinology · doi:10.1155/2022/3180004 · Cited by 8
Mai, F., Kordt, M., Bergmann‐Ewert, W., Reisinger, E. C., & Müller‐Hilke, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1359475 · Cited by 7
Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease coursePreprint
Muri, J., Cecchinato, V., Cavalli, A., Shanbhag, A. A., Matkovic, M., Biggiogero, M., Maida, P. A., Moritz, J., Toscano, C., Ghovehoud, E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.23.493121 · Cited by 6
Keskın, O., Oral, H., Sahin, T., Kav, T., & Parlak, E. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1039202 · Cited by 6
“The effectiveness of currently used vaccines in preventing the disease has been demonstrated in many studies (6, 7).”
BackgroundKatoto, P. D., Kakubu, M. A., Tamuzi, J. L., Brand, A., Ayuk, A. C., Byamungu, L. N., Wiysonge, C. S., & Gray, G. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2204154 · Cited by 5
“Serious adverse effects were uncommon in randomized clinical trials (RCTs) involving adolescents, and young adults participants, and vaccination effectiveness was near to 100% [13,14].”
BackgroundJohnson, K. E., Pasco, R. F., Woody, S., Lachmann, M., Johnson-León, M., Bhavnani, D., Klima, J., Paltiel, A. D., Fox, S. J., & Ancel, L. W. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011715 · Cited by 5
Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19
Cass, S. P., Nicolau, D. V., Baker, J. R., Mwasuku, C. M., Ramakrishnan, S., Mahdi, M., Barnes, P. J., Donnelly, L., Martínez-Nuñez, R. T., Russell, R. E. K., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00919-2023 · Cited by 7
Esteve-Palau, E., González-Cuevas, A., Guerrero, M. E., Garcia-Terol, C., Alvarez, M. C., Garcia, G., Moreno, E., Medina, F., Casadevall, D., & Díaz-Brito, V. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac239 · Cited by 8
Pannus, P., Depickère, S., Kemlin, D., Houben, S., Neven, K. Y., Heyndríckx, L., Míchiels, J., Willems, E., Craeye, S. D., Francotte, A., et al. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001308 · Cited by 6
McDonald, C. I., Parry, P. I., & Rhodes, P. (2024) · Journal of Psychiatry and Psychiatric Disorders · doi:10.26502/jppd.2572-519x0209 · Cited by 4
Méndez-Lizárraga, C. A., Chacón‐Cruz, E., Carrillo-Meza, R., Hernández-Milán, N. S., Inustroza-Sánchez, L. C., Ovalle-Marroquín, D. F., Machado-Contreras, J. R., Zuñiga, O. C., Bejarano-Ramírez, V., Aguilar-Aguayo, C., et al. (2022) · Vaccines · doi:10.3390/vaccines10081196 · Cited by 7
“Finally, the clinical trial from Pfizer-BioNTech only reported adverse total adverse events by severity [37].”
MethodEfficacy of the COVID ‐19 vaccine in heart transplant recipients: what we know and what we ignore
Crespo-Leiro, M. G., Barge‐Caballero, E., & Gustafsson, F. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2302 · Cited by 5
Ballestero, M. F. M., de Souza, R. L. P., Sakae, T. M., da Costa, L. G. V., Furlanetti, L. L., & de Oliveira, R. S. (2022) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2022ao0067 · Cited by 9
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.